Compare iShares MSCI Malaysia ETF (EWM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares MSCI Malaysia ETF trades at $26.86 (market cap $241.37M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 31.2× iShares MSCI Malaysia ETF's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 68 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWM | SYRE | |
|---|---|---|
Market Cap | $241.37M | $7.52B |
Volume | 74,129 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $108.92 |
52-Week Low | $25.47 | $22.18 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM trades at $26.96, up 0.63% today, but technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure. Key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. Recent news highlights external risks, such as regional haze-related disruptions affecting operations in Malaysia, which could impact investor confidence.
The outlook remains cautious due to weak technicals and limited fundamental data. Risks include environmental disruptions and market volatility. Investment opportunities hinge on upcoming financial disclosures to validate growth prospects, while current sentiment leans bearish amid uncertainty.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
